Literature DB >> 14693566

In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.

Dongeun Yong1, Jong Hwa Yum, Kyungwon Lee, Yunsop Chong, Sung Hak Choi, Jae Keol Rhee.   

Abstract

In vitro activities of DA-7867, a novel oxazolidinone, were compared to those of linezolid and commonly used antimicrobials. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested, </=0.25 micro g/ml, and it was more potent than linezolid.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14693566      PMCID： PMC310204          DOI： 10.1128/AAC.48.1.352-357.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Impact of antimicrobial agents on human intestinal microflora.

Authors:  C E Nord; C Edlund
Journal:  J Chemother       Date:  1990-08       Impact factor: 1.714

2.  In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.

Authors:  A C Fluit; F-J Schmitz; J Verhoef; D Milatovic
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

3.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

Authors:  G M Eliopoulos; C B Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin.

Authors:  Jeong Won Shin; Dongeun Yong; Myung Sook Kim; Kyung Hee Chang; Kyungwon Lee; June Myung Kim; Yunsop Chong
Journal:  J Infect Chemother       Date:  2003-03       Impact factor: 2.211

6.  Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria.

Authors:  O A Phillips; V O Rotimi; W Y Jamal; M Shahin; T L Verghese
Journal:  J Chemother       Date:  2003-04       Impact factor: 1.714

Review 7.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790

8.  In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.

Authors:  Dong Eun Yong; Hee-Jin Cheong; Yang Soo Kim; Yeon Joon Park; Woo-Joo Kim; Jun Hee Woo; Kyung Won Lee; Moon Won Kang; Youn-Sung Choo
Journal:  J Korean Med Sci       Date:  2002-12       Impact factor: 2.153

9.  Prevalence of cefotaxime resistance in group B streptococcus isolates from Osaka, Japan.

Authors:  Yoshiro Morikawa; Miyoshi Kitazato; Chihiro Katsukawa; Aki Tamaru
Journal:  J Infect Chemother       Date:  2003-06       Impact factor: 2.211

10.  In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Francoise Miegeville; Pierre-Yves Donnio; Denis Bugnon; Gilles Potel
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790
View more
  5 in total

1.  In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.

Authors:  Lucio Vera-Cabrera; Jorge Castro-Garza; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Kym Blackwood; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  In vitro and in vivo activities of DA-7867, a new oxazolidinone, against aerobic gram-positive bacteria.

Authors:  Eun Jeong Yoon; Yeong Woo Jo; Sung Hak Choi; Tae Ho Lee; Jae Keol Rhee; Moohi Yoo; Mi Ja Shim; Eung Chil Choi
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

Authors:  Jeffrey B Locke; John Finn; Mark Hilgers; Gracia Morales; Shahad Rahawi; Kedar G C; Juan José Picazo; Weonbin Im; Karen Joy Shaw; Jeffrey L Stein
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

4.  Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea.

Authors:  Jong Hwa Yum; Sung Hak Choi; Dongeun Yong; Yunsop Chong; Weon Bin Im; Dong-Kwon Rhee; Kyungwon Lee
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

5.  In vitro activities of panduratin A against clinical Staphylococcus strains.

Authors:  Yaya Rukayadi; Kwanghyung Lee; Sunghwa Han; Dongeun Yong; Jae-Kwan Hwang
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.